FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
FATE THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.86+0.07 (+3.91%)
Close on Oct 19, 2026
- Market cap
- $223.94M
- P/E (TTM)
- –
- Dividend yield
- –
Fate Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Fate Therapeutics | Industry median |
|---|---|---|
| Market Cap | $222.87M | $164.85M |
| Enterprise Value | $69.07M | $87.06M |
| PS Ratio | 34.33 | 3.60 |
| PB Ratio | 1.45 | 2.03 |
| P/TBV Ratio | 1.45 | 2.31 |
Enterprise value
| Measure | Fate Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 10.64 | 2.43 |
Income (trailing twelve months)
| Measure | Fate Therapeutics | Industry median |
|---|---|---|
| Revenue | $6.49M | $57.94M |
| Operating Income | -$133.59M | -$21.44M |
| Net Income | -$126.00M | -$22.46M |
| EBITDA | -$121.60M | -$16.91M |
| EPS (Diluted) | -$1.05 | -$0.83 |
Margins
| Measure | Fate Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -2058.1% | -44.5% |
| Profit Margin | -1941.1% | -39.2% |
| EBITDA Margin | -1873.4% | -31.3% |
| FCF Margin | -1627.2% | -8.85% |
Returns
| Measure | Fate Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -60.7% | -53.1% |
| Return on Assets (ROA) | -39.9% | -41.0% |
| Return on Invested Capital (ROIC) | -552.9% | -32.0% |
| Return on Capital Employed (ROCE) | -58.7% | -37.8% |
Growth
| Measure | Fate Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -23.4% | 6.01% |
| Revenue Growth (3Y CAGR) | -59.0% | 2.25% |
| Revenue Growth (5Y CAGR) | -26.7% | 6.42% |
Balance sheet
| Measure | Fate Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $153.80M | $62.42M |
| Net Cash (Debt) | $153.80M | $15.68M |
| Net Cash Per Share | $1.28 | $0.66 |
| Equity (Book Value) | $153.44M | $48.79M |
| Book Value Per Share | $1.28 | $1.36 |
| Tangible Book Value | $153.44M | $23.06M |
| Working Capital | $125.36M | $75.77M |
Financial position
| Measure | Fate Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.85 | 3.30 |
| Quick Ratio | 4.74 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Fate Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$101.91M | -$12.35M |
| Capital Expenditures | -$3.71M | -$1.06M |
| Free Cash Flow | -$105.62M | -$20.28M |
| FCF Per Share | -$0.88 | -$0.42 |
Efficiency
| Measure | Fate Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.02 | 0.38 |
| Revenue Per Employee | $40.32K | $398.96K |
| Profits Per Employee | -$782.58K | -$703.34K |
| Employee Count | 161 | 74 |
Dividends and yields
| Measure | Fate Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -56.5% | -22.7% |
| FCF Yield | -47.4% | -9.07% |
Shares
| Measure | Fate Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 119,821,000 | 58,179,650 |
| Shares Change (YoY) | 1.31% | 11.1% |
| Shares Change (QoQ) | 0.36% | 0.54% |
| Float | 89,967,100 | 49,173,100 |
| Shares Held by Insiders | 24.9% | 11.6% |
| Shares Held by Institutions | 59.9% | 59.4% |
Scores
| Measure | Fate Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -8.43 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Fate Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.